T TRANSMEDICS GROUP INC
| Market Cap | $3.45B |
| P/E Ratio | 20.68 |
| Forward P/E | 27.21 |
| Dividend Yield | — |
| Beta | 2.08 |
| 52W Range | $67.67 - $150.42 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Medical Devices |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.01% | $1.32M | 10,828 | Add 90.30% |
Insider Trading
| Insider Name of the company insider who made the trade 15 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Weill David | Sale | 3,571 | $146.82 | $524.29K | 04 Mar 2026 | 06 Mar 2026 |
| Hernandez GerardoChief Financial Officer | Sale | 5,912 | $147.21 | $870.31K | 04 Mar 2026 | 04 Mar 2026 |
| Hernandez GerardoChief Financial Officer | Sale | 1,324 | $147.21 | $194.91K | 04 Mar 2026 | 04 Mar 2026 |
| Lovell Stephanie | Sale | 1,193 | $149.62 | $178.50K | 04 Mar 2026 | 06 Mar 2026 |
| David WeillDirector | Sale | 3,571 | $146.82 | $524.29K | 04 Mar 2026 | 06 Mar 2026 |
| Stephanie LovellDirector | Sale | 1,193 | $149.62 | $178.50K | 04 Mar 2026 | 06 Mar 2026 |
| Corcoran NicholasSee remarks | Sale | 2,966 | $139.12 | $412.63K | 02 Mar 2026 | 04 Mar 2026 |
| Ranganath Anil P.See remarks | Sale | 864 | $139.12 | $120.20K | 02 Mar 2026 | 04 Mar 2026 |
| Hernandez GerardoChief Financial Officer | Sale | 375 | $139.12 | $52.17K | 02 Mar 2026 | 04 Mar 2026 |
| Hernandez GerardoChief Financial Officer | Sale | 920 | $139.62 | $128.45K | 04 Dec 2025 | 05 Dec 2025 |
| Weill David | Sale | 5,000 | $138.64 | $693.20K | 03 Dec 2025 | 05 Dec 2025 |
| Ranganath Anil P.Senior Vice President, General Counsel and Secretary | Sale | 3,000 | $145.22 | $435.66K | 25 Nov 2025 | 26 Nov 2025 |
| Hassanein Waleed HPresident & CEO | Buy | 8,775 | $114.00 | $1.00M | 17 Nov 2025 | 18 Nov 2025 |
| Basile Edward M | Sale | 4,142 | $130.45 | $540.32K | 29 Oct 2025 | 31 Oct 2025 |
| Edward M BasileDirector | Sale | 4,142 | $130.45 | $540.32K | 29 Oct 2025 | 31 Oct 2025 |
Frequently Asked Questions
What is TMDX stock price today?
TRANSMEDICS GROUP INC (TMDX) is currently trading at $100.69. The stock has a 52-week range of $67.67 to $150.42 and a market capitalization of $3.45B.
Is TMDX a good stock to buy in 2026?
TRANSMEDICS GROUP INC has a P/E ratio of 20.7 (forward P/E: 27.2), a dividend yield of none, and 1-year performance of +41.9%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling TMDX stock?
There have been 15 insider transactions for TMDX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has TMDX stock performed over the past year?
TRANSMEDICS GROUP INC (TMDX) has returned +41.9% over the past 12 months. The stock traded between $67.67 and $150.42 during this period, and is currently at $100.69.
Which hedge funds own TMDX (TRANSMEDICS GROUP INC)?
1 tracked hedge funds currently hold TMDX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is TMDX's market cap and valuation?
TRANSMEDICS GROUP INC (TMDX) has a market capitalization of $3.45B. The trailing P/E ratio is 20.7 and forward P/E is 27.2. The stock is classified in the Healthcare sector.
What is TMDX's revenue and profitability?
TRANSMEDICS GROUP INC reported revenue of $605.49M with net income of $190.29M and a profit margin of 0.31%. The stock has a beta of 2.08.
What sector is TMDX in and who are its biggest institutional holders?
TRANSMEDICS GROUP INC (TMDX) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.